Inhibition of EGFR tyrosine-kinase in NSCLC treatment: The Hungarian experience with gefitinib in the context of an expanded access programme

G. Ostoros, Revekka Harisi, Gabor Kovacs, Jozsef Horti, L. Géczi, Klara Szondy, Marta Orosz, Eniko Ferenczi, Eva Ruby, B. Döme

Research output: Article

3 Citations (Scopus)

Abstract

The ZD1839 (Iressa, gefitinib) treatment in phase I trials for patients with advanced non-small cell lung cancer (NSCLC) was associated with disease stabilization and tumor regression. The aim of this study was to analyze the efficacy of gefitinib monotherapy as a second- or third-line treatment for locally-advanced and advanced NSCLC. Data for 50 patients were analyzed. Patients were treated at 5 centers in Hungary as part of the gefitinib Expanded Access Programme (EAP). The response rate was 10% (all partial responses), with disease stabilization in 46% of patients. Disease progression was observed in 44% of patients. The median survival according to the Kaplan-Meier method was 8 months. Median survival of patients with adenocarcinoma was significantly increased compared with squamous cell carcinoma and, of the patients responding to therapy, 80% had adenocarcinoma. The 1-year survival rate was 34%. All patients were evaluable for safety; the adverse events seen with gefitinib were generally mild and only two patients had to be withdrawn from the study due to adverse events. The Hungarian experience suggests gefitinib therapy is effective and well tolerated.

Original languageEnglish
Pages (from-to)4759-4762
Number of pages4
JournalAnticancer Research
Volume25
Issue number6 C
Publication statusPublished - nov. 2005

Fingerprint

Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Therapeutics
Adenocarcinoma
gefitinib
Survival
Hungary
Disease Progression
Squamous Cell Carcinoma
Survival Rate
Safety

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Inhibition of EGFR tyrosine-kinase in NSCLC treatment : The Hungarian experience with gefitinib in the context of an expanded access programme. / Ostoros, G.; Harisi, Revekka; Kovacs, Gabor; Horti, Jozsef; Géczi, L.; Szondy, Klara; Orosz, Marta; Ferenczi, Eniko; Ruby, Eva; Döme, B.

In: Anticancer Research, Vol. 25, No. 6 C, 11.2005, p. 4759-4762.

Research output: Article

Ostoros, G. ; Harisi, Revekka ; Kovacs, Gabor ; Horti, Jozsef ; Géczi, L. ; Szondy, Klara ; Orosz, Marta ; Ferenczi, Eniko ; Ruby, Eva ; Döme, B. / Inhibition of EGFR tyrosine-kinase in NSCLC treatment : The Hungarian experience with gefitinib in the context of an expanded access programme. In: Anticancer Research. 2005 ; Vol. 25, No. 6 C. pp. 4759-4762.
@article{2459014b415e42c0880ce3e7cd4cf95a,
title = "Inhibition of EGFR tyrosine-kinase in NSCLC treatment: The Hungarian experience with gefitinib in the context of an expanded access programme",
abstract = "The ZD1839 (Iressa, gefitinib) treatment in phase I trials for patients with advanced non-small cell lung cancer (NSCLC) was associated with disease stabilization and tumor regression. The aim of this study was to analyze the efficacy of gefitinib monotherapy as a second- or third-line treatment for locally-advanced and advanced NSCLC. Data for 50 patients were analyzed. Patients were treated at 5 centers in Hungary as part of the gefitinib Expanded Access Programme (EAP). The response rate was 10{\%} (all partial responses), with disease stabilization in 46{\%} of patients. Disease progression was observed in 44{\%} of patients. The median survival according to the Kaplan-Meier method was 8 months. Median survival of patients with adenocarcinoma was significantly increased compared with squamous cell carcinoma and, of the patients responding to therapy, 80{\%} had adenocarcinoma. The 1-year survival rate was 34{\%}. All patients were evaluable for safety; the adverse events seen with gefitinib were generally mild and only two patients had to be withdrawn from the study due to adverse events. The Hungarian experience suggests gefitinib therapy is effective and well tolerated.",
keywords = "Expanded Access Programme, Gefitinib, Non-small cell lung cancer",
author = "G. Ostoros and Revekka Harisi and Gabor Kovacs and Jozsef Horti and L. G{\'e}czi and Klara Szondy and Marta Orosz and Eniko Ferenczi and Eva Ruby and B. D{\"o}me",
year = "2005",
month = "11",
language = "English",
volume = "25",
pages = "4759--4762",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6 C",

}

TY - JOUR

T1 - Inhibition of EGFR tyrosine-kinase in NSCLC treatment

T2 - The Hungarian experience with gefitinib in the context of an expanded access programme

AU - Ostoros, G.

AU - Harisi, Revekka

AU - Kovacs, Gabor

AU - Horti, Jozsef

AU - Géczi, L.

AU - Szondy, Klara

AU - Orosz, Marta

AU - Ferenczi, Eniko

AU - Ruby, Eva

AU - Döme, B.

PY - 2005/11

Y1 - 2005/11

N2 - The ZD1839 (Iressa, gefitinib) treatment in phase I trials for patients with advanced non-small cell lung cancer (NSCLC) was associated with disease stabilization and tumor regression. The aim of this study was to analyze the efficacy of gefitinib monotherapy as a second- or third-line treatment for locally-advanced and advanced NSCLC. Data for 50 patients were analyzed. Patients were treated at 5 centers in Hungary as part of the gefitinib Expanded Access Programme (EAP). The response rate was 10% (all partial responses), with disease stabilization in 46% of patients. Disease progression was observed in 44% of patients. The median survival according to the Kaplan-Meier method was 8 months. Median survival of patients with adenocarcinoma was significantly increased compared with squamous cell carcinoma and, of the patients responding to therapy, 80% had adenocarcinoma. The 1-year survival rate was 34%. All patients were evaluable for safety; the adverse events seen with gefitinib were generally mild and only two patients had to be withdrawn from the study due to adverse events. The Hungarian experience suggests gefitinib therapy is effective and well tolerated.

AB - The ZD1839 (Iressa, gefitinib) treatment in phase I trials for patients with advanced non-small cell lung cancer (NSCLC) was associated with disease stabilization and tumor regression. The aim of this study was to analyze the efficacy of gefitinib monotherapy as a second- or third-line treatment for locally-advanced and advanced NSCLC. Data for 50 patients were analyzed. Patients were treated at 5 centers in Hungary as part of the gefitinib Expanded Access Programme (EAP). The response rate was 10% (all partial responses), with disease stabilization in 46% of patients. Disease progression was observed in 44% of patients. The median survival according to the Kaplan-Meier method was 8 months. Median survival of patients with adenocarcinoma was significantly increased compared with squamous cell carcinoma and, of the patients responding to therapy, 80% had adenocarcinoma. The 1-year survival rate was 34%. All patients were evaluable for safety; the adverse events seen with gefitinib were generally mild and only two patients had to be withdrawn from the study due to adverse events. The Hungarian experience suggests gefitinib therapy is effective and well tolerated.

KW - Expanded Access Programme

KW - Gefitinib

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=28444481275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28444481275&partnerID=8YFLogxK

M3 - Article

C2 - 16334173

AN - SCOPUS:28444481275

VL - 25

SP - 4759

EP - 4762

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6 C

ER -